Literature DB >> 20015233

Restriction point control of the mammalian cell cycle via the cyclin E/Cdk2:p27 complex.

Riaan Conradie1, Frank J Bruggeman, Andrea Ciliberto, Attila Csikász-Nagy, Bela Novák, Hans V Westerhoff, Jacky L Snoep.   

Abstract

Numerous top-down kinetic models have been constructed to describe the cell cycle. These models have typically been constructed, validated and analyzed using model species (molecular intermediates and proteins) and phenotypic observations, and therefore do not focus on the individual model processes (reaction steps). We have developed a method to: (a) quantify the importance of each of the reaction steps in a kinetic model for the positioning of a switch point [i.e. the restriction point (RP)]; (b) relate this control of reaction steps to their effects on molecular species, using sensitivity and co-control analysis; and thereby (c) go beyond a correlation towards a causal relationship between molecular species and effects. The method is generic and can be applied to responses of any type, but is most useful for the analysis of dynamic and emergent responses such as switch points in the cell cycle. The strength of the analysis is illustrated for an existing mammalian cell cycle model focusing on the RP [Novak B, Tyson J (2004) J Theor Biol230, 563-579]. The reactions in the model with the highest RP control were those involved in: (a) the interplay between retinoblastoma protein and E2F transcription factor; (b) those synthesizing the delayed response genes and cyclin D/Cdk4 in response to growth signals; (c) the E2F-dependent cyclin E/Cdk2 synthesis reaction; as well as (d) p27 formation reactions. Nine of the 23 intermediates were shown to have a good correlation between their concentration control and RP control. Sensitivity and co-control analysis indicated that the strongest control of the RP is mediated via the cyclin E/Cdk2:p27 complex concentration. Any perturbation of the RP could be related to a change in the concentration of this complex; apparent effects of other molecular species were indirect and always worked through cyclin E/Cdk2:p27, indicating a causal relationship between this complex and the positioning of the RP.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20015233     DOI: 10.1111/j.1742-4658.2009.07473.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  17 in total

1.  Nongenetic origins of cell-to-cell variability in B lymphocyte proliferation.

Authors:  Simon Mitchell; Koushik Roy; Thomas A Zangle; Alexander Hoffmann
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-07       Impact factor: 11.205

Review 2.  The dynamic control of signal transduction networks in cancer cells.

Authors:  Walter Kolch; Melinda Halasz; Marina Granovskaya; Boris N Kholodenko
Journal:  Nat Rev Cancer       Date:  2015-08-20       Impact factor: 60.716

3.  SCF-mediated Cdh1 degradation defines a negative feedback system that coordinates cell-cycle progression.

Authors:  Hidefumi Fukushima; Kohei Ogura; Lixin Wan; Ying Lu; Victor Li; Daming Gao; Pengda Liu; Alan W Lau; Tao Wu; Marc W Kirschner; Hiroyuki Inuzuka; Wenyi Wei
Journal:  Cell Rep       Date:  2013-08-22       Impact factor: 9.423

Review 4.  Synthetic biology and regulatory networks: where metabolic systems biology meets control engineering.

Authors:  Fei He; Ettore Murabito; Hans V Westerhoff
Journal:  J R Soc Interface       Date:  2016-04-13       Impact factor: 4.118

5.  Activation of protein synthesis in mouse uterine epithelial cells by estradiol-17β is mediated by a PKC-ERK1/2-mTOR signaling pathway.

Authors:  Yuxiang Wang; Liyin Zhu; Satu Kuokkanen; Jeffrey W Pollard
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-02       Impact factor: 11.205

6.  Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2.

Authors:  Alicia A Goyeneche; Erin E Seidel; Carlos M Telleria
Journal:  Invest New Drugs       Date:  2011-03-22       Impact factor: 3.850

7.  Erk in kidney diseases.

Authors:  Denis Feliers; Balakuntalam S Kasinath
Journal:  J Signal Transduct       Date:  2011-04-07

8.  Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy.

Authors:  Carlos D Gamarra-Luques; Alicia A Goyeneche; Maria B Hapon; Carlos M Telleria
Journal:  BMC Cancer       Date:  2012-06-22       Impact factor: 4.430

9.  Dynamic expression profiles from static cytometry data: component fitting and conversion to relative, "same scale" values.

Authors:  Jayant Avva; Michael C Weis; R Michael Sramkoski; Sree N Sreenath; James W Jacobberger
Journal:  PLoS One       Date:  2012-07-12       Impact factor: 3.240

10.  Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDA-MB-231.

Authors:  Mariel Núñez; Vanina Medina; Graciela Cricco; Máximo Croci; Claudia Cocca; Elena Rivera; Rosa Bergoc; Gabriela Martín
Journal:  BMC Pharmacol Toxicol       Date:  2013-01-11       Impact factor: 2.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.